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Background: Differentiating between benign and malignant causes of obstructive jaundice can be
challenging, even with the advanced imaging and endoscopic techniques currently available. In patients
with obstructive jaundice, the predictive accuracy of bilirubin levels at presentation was examined in order
to determine whether such data could be used to differentiate between malignant and benign disease.
Methods: A total of 1026 patients with obstructive jaundice were identified. Patients were divided into
benign and malignant groups. The benign patients were subgrouped into those with choledocholithiasis
and those with inflammatory strictures of the biliary tree. Bilirubin levels at presentation and other
demographic data were obtained from case records.
Results: Area under the curve (AUC) values for bilirubin as a predictor of malignancy were highly
significant for all benign presentations and for those with benign biliary strictures (AUC: 0.8 for both
groups; P < 0.001). A bilirubin level > 100 mmol/l was determined to provide the optimum sensitivity and
specificity for malignancy in all patients and in those without choledocholithiasis (71.9% and 86.9%,
71.9% and 88.0%, respectively). The application of a bilirubin level > 250 mmol/l achieved specificities of
97.1% and 98.0% in each subgroup of patients, respectively.
Conclusions: In patients with obstructive jaundice, bilirubin levels in isolation represent an important
tool for discriminating between benign and malignant underlying causes.
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Introduction
Differentiating between benign and malignant causes of obstruc-
tive jaundice can be challenging, even with the advanced imaging
and endoscopic techniques currently available. Preoperative his-
tological confirmation of malignancy is not always possible
because of the complex regional anatomy of the pancreaticobil-
iary system. Endoscopic ultrasound (EUS), direct cholangioscopy
and endocystoscopy have increased the probability of obtaining
preoperative tissue for analysis, but it is widely recognized by
hepatobiliary specialists that, out of concern that a potentially
resectable lesion may be missed, patients may undergo resection
for suspicious lesions without histological confirmation of can-
cer.1,2 Even when the surgeon seeks to obtain intraoperative tissue
confirming malignancy prior to proceeding to resection, the
patient is exposed to considerable dissection at the time of surgery
in order to allow representative tissue samples to be obtained. The
decision to proceed to an explorative operation with or without
resection is frequently based on accumulated radiological, clinical
and biochemical predictors and subsequent discussion at a mul-
tidisciplinary team (MDT) meeting.
Together with radiological imaging, tumour markers, such as
CA19-9 (carbohydrate antigen 19-9) levels, are routinely used in
many centres to assess patients who present with suspicious pan-
creaticobiliary lesions; these markers have been shown to be of
some value in differentiating between benign and malignant
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disease.3 The CA19-9 : bilirubin ratio has been previously shown
to improve accuracy in attempts to characterize biliary strictures.4
This study examined the predictive accuracy of bilirubin levels at
presentation in order to determine whether these values can dif-
ferentiate between benign and malignant disease.
Materials and methods
The case records of over 1000 patients presenting with obstructive
jaundice during the period 2008–2010 were identified from endo-
scopic retrograde cholangiopancreatography (ERCP) records,
interventional radiological procedures and operative logbooks.
The selection of patients who had undergone interventional pro-
cedures ensured that all selected patients had undergone multi-
modal assessment of jaundice and that tissue was frequently
available to confirm a benign or malignant diagnosis.
Demographic data such as age, final diagnosis and bilirubin
level at initial presentation were recorded. The final diagnosis was
made using histological tissue (including frozen sections obtained
at the time of surgical exploration, formal histology of resected
specimens, radiological/laparoscopic biopsies of disseminated or
primary disease, and brushings from ERCP), interval radiological
imaging (consisting of at least two cross-sectional scans taken6
months apart, each discussed at a specialist hepatobiliary MDT
meeting and showing no disease progression in cases of benign
disease) and findings at interventions such as ERCP or surgery.
Patients were divided into benign and malignant groups accord-
ing to their underlying pathology. The benign-disease group was
subdivided into those with choledocholithiasis and those with
inflammatory strictures of the biliary tree. Bilirubin levels were
evaluated for accuracy at both the initial presentation with
obstructive jaundice and again after initial imaging had excluded
stone disease as a cause of the jaundice. Ethical approval was not
required for this study. A literature search using PubMed was
undertaken for comparative data from previously published
manuscripts on the sensitivity and specificity of radiological
imaging and tumour markers in determining malignancy. Data
were analysed with receiver operating characteristic (ROC) and
area under the curve (AUC) values using MedCalc® Version 9.3
(MedCalc Software, Mariakerke, Belgium). Receiver operating
characteristics are graphical plots of the sensitivity vs. false posi-
tive rate for a binary classifier system (i.e. whether a patient has
benign or malignant disease) (Fig. 1). If the AUC value derived
from the ROC curve is 1, the predictor is 100% sensitive and
specific; if the AUC is 0.5, the predictor is little better than chance
alone.
Results
A total of 1026 patients with obstructive jaundice were identified.
Demographic data and bilirubin levels by aetiology are displayed
in Table 1. Table 2 shows the final diagnoses in this cohort of
patients. Stone disease accounted for the majority of patients with
obstructive jaundice caused by benign disease (83.8%). The
secondmost common cause was chronic pancreatitis (4.6%). Pan-
creatic adenocarcinoma was the most common diagnosis in
patients with malignant disease (36.6%).
Table 3 demonstrates the sensitivity and specificity of bilirubin
in predicting malignancy in all patients presenting with obstruc-
tive jaundice. Bilirubin levels of 100 mmol/l were found to be
71.9% sensitive and 86.9% specific for malignancy (positive like-
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Figure 1 Receiver operating characteristic (ROC) curves for bilirubin and prediction of malignancy with area under the curve values for (a)
all patients with either benign or malignant causes of jaundice and (b) patients with common bile duct stones excluded. The bold line
represents the ROC curve; faint lines represent the range of values
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ity increased. Bilirubin levels of >250 mmol/l were 97.1% specific
in predicting malignancy (positive likelihood ratio: 11.3). Table 4
demonstrates the accuracy of bilirubin after imaging had excluded
choledocholithiasis. The benign-disease group in this table
included patients with strictures of the biliary tree caused by
various non-malignant aetiologies. Bilirubin levels were found to
be consistently accurate in excluding malignancy. Values of
100 mmol/l were 71.9% sensitive and 88.0% specific in detecting
malignancy (positive likelihood ratio: 5.5). Values of >250 mmol/l
were 98.0% specific in detecting malignancy (positive likelihood
ratio: 11.3).
Area under the curve values for bilirubin as a predictor for
malignancy were highly significant, both for all benign presenta-
tions (Fig. 1a) and for those with benign biliary strictures only
(Fig. 1b) (AUC: 0.8 for both groups; P < 0.0001). Optimum sen-
sitivity and specificity for malignancy was determined to be at a
bilirubin level of >100 mmol/l for all patients and for those with
biliary strictures only (71.9% and 86.9%, 71.9% and 88.0%,
respectively). Specificities of 97.1% and 98.0% were obtained
in each group of patients, respectively, at a bilirubin level
>250 mmol/l.
Discussion
The results suggest that, even in isolation, bilirubin levels are an
important discriminator in patients with obstructive jaundice.
Although sensitivity inevitably drops with increasing levels of
bilirubin, a markedly raised bilirubin (100 mmol/l) has an
important positive predictive value for the presence of malig-
nancy. These findings are supported by other papers which have
examined bilirubin levels in malignant disease. Previous studies
have also found bilirubin to predict malignancy with AUC values
of 0.85 and quoted bilirubin levels of 84 mmol/l (sensitivity and
specificity of 98.6% and 59.3%, respectively) and 75 mmol/l.6,7
These values are commensurate with the results from the current
data. A previous study has reported that patients presenting with
malignant obstructive jaundice have a median bilirubin level of
160 mmol/l and that only 23% of patients have a bilirubin level
<100 mmol/l and a rate of rise of bilirubin of 100 mmol/l per
week.8 To the authors’ knowledge, the data presented here are
sourced from the largest cohort of such patients (>1000 patients)
reported in the literature.
Although we do not suggest that bilirubin alone can be used to
characterize biliary strictures, it is useful to compare these results
with those from more generally accepted modalities used for
assessment, such as tumour markers and cross-sectional imaging.
The data presented in Table 53,9–17 are not intended to represent an
exhaustive review of the literature, but, rather, to demonstrate
data from individual studies and systematic reviews that have
examined the accuracy of CA19-9, magnetic resonance imaging
(MRI), computed tomography (CT), positron emission tomogra-
phy (PET-CT) and EUS in diagnosing the cause of obstructive
jaundice. However, although the meta-analysis investigating MRI
found this modality to be very sensitive and specific in diagnosing
the aetiology of obstructive jaundice, it included patients with
stone disease.12
The comparison indicates that bilirubin levels may be a useful
adjunct when used together with these other modalities. Bilirubin
levels at presentationmay be of use to the clinician in several ways.
A very high bilirubin level may prompt a more detailed evaluation
Table 1 Demographic data for patients with underlying benign or malignant pathology
Total Benign pathology Malignant pathology Significance
Number of patients, n 1026 480 546 –
Gender, n (%) 1.000
Male 556 (54.2%) 254 (53.1%) 302 (55.1%)
Female 470 (45.8%) 224 (46.9%) 246 (44.9%)
Median age (range), years 71 (22–98) 70 (22–98) 71 (23–86) 0.331
Median bilirubin (range), mmol/l (including CBD stones) – 59 (19–400) 200 (26–723) <0.001
Median bilirubin (range), mmol/l (excluding CBD stones) – 63 (30–400) 200 (26–723) <0.001
CBD, common bile duct; SD, standard deviation







Common bile duct stones 428 89.2
Chronic pancreatitis 22 4.6
Post-cholecystectomy stricture 17 3.5
Autoimmune pancreatitis 11 2.3
Primary sclerosing cholangitis 2 0.4
Malignant pathology
Pancreatic ductal adenocarcinoma 200 36.6
Gallbladder cancer 146 26.7
Hilar cholangiocarcinoma 89 16.3
Metastatic disease with biliary
obstruction
42 7.7
Distal cholangiocarcinoma 31 5.7
Ampullary adenocarcinoma 31 5.7
Duodenal adenocarcinoma 7 1.3
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(including for tumour markers) to exclude underlying malig-
nancy and may lower the threshold for referring a patient to a
tertiary unit. For the hepatopancreatobiliary specialist faced with
a patient who has a stricture of unknown aetiology, bilirubin level
may represent another factor within amultimodal assessment that
prompts an exploration with or without resection.
Possible reasons why bilirubin levels are lower in patients with
benign disease may refer to the fact that patients with stone disease
present earlier as a result of associated pain or sepsis from bacter-
aemia within the biliary tree. As a consequence, bilirubin levels in
these patients at presentation are lower than those in patients with
malignant disease, in whom jaundice (which is not always imme-
Table 3 Bilirubin level and likelihood of malignancy in all patients with either benign or malignant causes for obstructive jaundice
Bilirubin
level, mmol/l
Sensitivity, % 95% confidence
interval











>50 87.7 84.4–90.5 38.8 34.4–43.4 59.0 75.9 1.4
>100 71.9 67.6–75.9 86.9 83.5–89.7 84.6 75.5 5.5
>150 60.4 55.9–64.8 92.7 90.0–94.9 89.2 70.0 8.3
>200 45.0 40.5–49.6 95.6 93.4–97.3 91.1 63.4 10.3
>250 32.9 28.7–37.3 97.1 95.1–98.4 91.9 59.1 11.3
>300 21.9 18.3–25.8 98.5 97.0–99.4 93.8 55.7 15.0
>350 13.1 10.2–16.5 99.2 97.9–99.8 94.0 53.3 15.7
>400 7.1 5.0–9.8 100 99.2–100 100 51.8 –
>500 1.3 0.5–2.7 100 99.2–100 100 50.3 –
Table 4 Bilirubin and probability of malignancy in patients, excluding those with common bile duct stones
Bilirubin level,
mmol/l
Sensitivity, % 95% confidence
interval











>50 87.7 84.4–90.5 36.0 22.9–50.8 92.9 23.4 1.4
>100 71.9 67.6–75.9 88.0 75.7–95.4 98.3 24.6 5.5
>150 60.4 55.9–64.8 90.0 78.2–96.6 98.3 19.1 8.3
>200 45.0 40.5–49.6 96.0 86.3–99.4 99.1 15.4 10.3
>250 32.9 28.7–37.3 98.0 89.3–99.7 99.4 13.2 11.3
>300 21.9 18.3–25.8 98.0 89.3–99.7 99.1 11.6 15.0
>350 13.1 10.2–16.5 98.0 89.3–99.7 98.4 10.5 15.7
>400 7.1 5.0–9.8 100 92.8–100 100 10.1 –
>500 1.3 0.5–2.7 100 92.8–100 100 9.5 –
Table 5 Sensitivity and specificity of bilirubin levels compared with other assessment modalities
Modality Patients, n Sensitivity, % Specificity, % AUC
Bilirubin, mmol/l 1026 0.82
>100 71.9 88.0
>250 31.9 98.0
CA19-93,9–11 776 68.4 72.5 0.75
MRCP12a 4711 95.0 97.0 0.96
ERCP13–15 220 74.0 94.0 –
EUS16 3532 78.0 84.0 –
CT17 92 – – 0.80
PET-CT15 46 89.0 74.0 –
aIncludes patients with jaundice secondary to stone disease
MRCP, magnetic resonance cholangiopancreatography; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonogra-
phy; CT, computed tomography; PET-CT, positron emission tomography
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diately apparent to the patient) is not infrequently the sole pre-
senting symptom. In addition, increasing degrees of biliary tract
dilatation may allow stones to disimpact from the distal common
bile duct, leading to a ‘ball–valve’ effect that prevents any further
increase in bilirubin levels. In biliary tract strictures without cho-
ledocholithiasis, the pathophysiology of an inflammatory stric-
ture (associated with improving and relapsing degrees of
obstruction) differs markedly from the inexorable progression of
a malignant process in the biliary tree.
Conclusions
In the clinical setting of the jaundiced patient, bilirubin levels in
isolation may represent an important early indicator of the likely
underlying cause of obstructive jaundice. Bilirubin levels are
always measured as a first test in any patient presenting with
jaundice. Clearly, a patient’s bilirubin level in isolation cannot
replace a careful clinical history and cross-sectional imaging.
However, bilirubin values can influence the subsequent work-up
of the patient. Optimum sensitivities and specificities are obtained
with bilirubin levels of 100 mmol/l. These findings highlight the
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